Cancer Clinical Trial -Dracen Pharmaceuticals-DRA-104-001

First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors.

Drug

DRP-104, atezolizumab

Phase

Phase I

Condition

Squamous Cell Head and Neck, Non-Small Cell Lung, Prostate

Keywords

Glutamine +